Newsletter · · Ashutosh Agarwal

Gene Editing's One-and-Done Cholesterol Moment Goes Mainstream - Biotech Pipeline: Gene/Cell, Neuro & Tools - Week of July 5–12, 2026

Gene, cell and neuro pipeline newsletter for the week of July 5 to 12, 2026. First human data show a single infusion base-editing the PCSK9 gene cut LDL cholesterol 62 percent, while investors debate whether biotech's rotation and a wave of $10 billion takeovers is a durable re-rating.

Biotech Pipeline: Gene/Cell, Neuro & Tools

Week of July 5–12, 2026: Gene Editing's One-and-Done Cholesterol Moment Goes Mainstream

For years, gene editing was a lab trick with a slide-deck promise: someday, one injection could rewrite a broken gene and fix a disease for good. This week, that "someday" showed up in plain-spoken form on a health podcast, with a working doctor marveling that a single infusion had knocked down a cholesterol gene by 88%, as good as a lifetime of pills. At the same time, the money noticed. Traders talked about CRISPR and Intellia "breaking out," a technical analyst called the whole biotech complex the place to rotate into, and a portfolio manager tallied three separate $10-billion-plus takeovers in a single month. The science and the flows are finally pointing the same direction.

TL;DR

  • One shot, cholesterol handled, for life. A physician-hosted podcast walked through the first human data on Eli Lilly's in-body gene editor (from its Verve acquisition): a single infusion cut the cholesterol-raising protein PCSK9 by 88% and dropped LDL ("bad") cholesterol by 62%, "as good or better than a statin." A second, different editing approach hit ~50% LDL and ~55% triglyceride reductions. (Good Medicine Podcast, Jul 7)
  • The money is rotating into biotech. A technical analyst flagged CRISPR (CRSP) and Intellia (NTLA) "breaking out" and biotech ETFs going "scorching higher" since mid-May, while a biotech investor counted three $10B+ buyouts in a month, Nuvalent, Apogee (by AbbVie), and Crinetics, calling this rally "driven by fundamentals," not 2021-style hype. (The KE Report, Jul 7; Investing Experts, Jul 8)
  • In Alzheimer's, the amyloid drugs are "the AZT of this era", and the field is pivoting to tau. Three separate podcasts landed on the same reality: today's plaque-clearing antibodies (Leqembi, Kisunla) genuinely work but only slow decline ~35-40%, and the next wave of news is about the other Alzheimer's protein, tau, with a big London conference next month teed up as the catalyst. (The Naked Scientists, Jul 7; Brain Talk, Jul 7)

What's new

The one-and-done cholesterol story finally has hard numbers, and they're big. The most striking thing on the podcasts this week wasn't from a Wall Street desk; it was two scientists on the Good Medicine Podcast talking through data that even they found startling. David Bearss, a longtime gene-editing researcher, put it simply: "in 2026, I can... just last month, we now have human data showing that a single infusion, so just giving one injection, can rewrite a gene in the liver and lower your cholesterol for life." The company is Verve Therapeutics, which Eli Lilly bought last year. Its editor, Verve-102, is delivered once, finds the PCSK9 gene in the liver, and changes a single letter of the DNA code. The reported result: "88% change in this protein, PCSK9, and... the LDL cholesterol lowered by 62%. So that's as good or better than you can get using a statin." The pitch, as Bearss framed it, is behavioral as much as biological, statins and PCSK9 shots already work, "it's just because we're trying to convince a person to take a drug... for a condition that has no symptoms," and people quit. A one-time edit removes the quitting problem entirely.

And it wasn't a one-off. The same episode flagged a second company using a different tool, CRISPR "molecular scissors" rather than single-letter base editing, against a different cholesterol gene, reporting a first-in-human "close to 50% reduction in LDL" and "about 55% reduction" in triglycerides. Two independent gene targets, two different technologies, same one-infusion concept. The hosts also relayed a telling bit of industry color: a Lilly dealmaker told Bearss the company is so flush from its weight-loss franchise (Mounjaro) that "they might announce a deal every week of buying new technology... they're literally buying everything." (Good Medicine Podcast)

A single baby's case shows how fast "bespoke" editing can move, and where it hits a wall. On RARECast, Johns Hopkins RNA scientist Jeff Collar walked through the case of baby K.J. Mildoon, born with CPS1 deficiency, a liver enzyme defect that lets toxic ammonia build up. A custom in-body base editor, the same mRNA-plus-lipid-nanoparticle format as the COVID vaccines, was designed, manufactured, and dosed in a matter of months instead of years, "because we already had a lot of this technology on the table" from the pandemic. The child is now "hitting developmental milestones... sitting up, he's walking, and he's starting to talk." Collar was careful not to oversell: "it's very important to not use the word cured," the baby has "a much milder form of the disease," and because the mRNA clears the body while only the correction stays, "he could be redosed" in a few years if needed. His bigger point is the size of the runway, there are "over 7,000 known monogenetic disorders" (single-gene diseases), and where the real bottleneck is: not the science, but the economics and rules around treatments that might help "one or just a handful of patients on the planet." He sketched a "plug-and-play" future where a handful of standard base editors and one standard delivery bubble get approved, and you just swap in the correction. (RARECast, Jul 9)

The tape and the technicals both say "rotate into biotech." On The KE Report, technical analyst TG Watkins described money leaving the crowded AI-and-semiconductor trade, noting memory names like Micron and SanDisk that "went up crazy... and then came crashing back down", and flowing into left-behind corners. Biotech was front and center: the ETFs (he watches ARCG and the leveraged LABU) "have had incredible moves" since mid-May, and among individual names, "I've been watching CRISPR, CRSP, and it actually started breaking out... and another one I like is NTLA, and that one's also been breaking out." His caution: after that run "they are a little bit high," and he wouldn't chase. He tied the whole move to a rates view, that the Fed won't be hiking, so risk-on, longer-duration bets like biotech and housing can work. (The KE Report)

That same rotation showed up on the IBD podcast, where the hosts watched the Nasdaq slip below its 50-day line and the semiconductor ETF gap down "for the first time since April" (with a memory-stock ETF down 25.5% from its high), while healthcare and the biotech ETF XBI kept climbing, "what pullback?" Eli Lilly hit a new high, and Jazz Pharmaceuticals and TG Therapeutics were flagged as fresh breakouts in the "profitable biotech" bucket. (Stock Market Today With IBD, Jul 7)

Deal-making is the fuel, and it's a "this time is different" argument. On Investing Experts, ROTY community lead Jonathan Faison made the bull case that this rally rests on fundamentals rather than froth. "Even within the last month, we saw three $10 billion-plus buyouts, with Nuvalent, Apogee, and Crinetics, Crinetics was announced today." Unlike 2021, he argued, the market isn't being flooded with "grab the money and run" IPOs; instead, cash-burning names are graduating into companies with approved products, and buyers are paying up (he noted community members who owned Crinetics woke up to a 100% premium). His honest caveat, repeated several times: "there's definitely a lot of optimism and euphoria for sure," and he treats takeouts as "the icing on the cake," not the thesis. (Investing Experts)

The debate

Is the biotech move a durable re-rating or a crowded momentum trade? This is the one place the week's podcasts genuinely argued both sides. The bull case is the strongest it's been in a while: real one-shot editing data, a wave of $10B+ takeovers, and money visibly rotating out of tech. Faison's framing, euphoria "driven by fundamentals", is the optimistic pole. But the same voices supplied the bear case unprompted. TG Watkins, who called the biotech move early, now says the names are "a little bit high" and openly wonders whether they "need to digest after their strong run-up since mid-May." Faison himself keeps flagging the "euphoria" and preaches patience, don't chase names that have run, wait for the "sell the news" pullbacks. And the whole rotation rests on a macro bet (that rates won't rise) that could reverse. The honest read: the fundamentals are real, but so is the crowding, and nobody this week argued the run can continue in a straight line.

RNA silencers vs. antisense, a quieter modality fight worth watching. Over on Biotech Hangout, the panel dug into a surprising clinical miss that bears on the broader "how do you switch off a bad gene" question. Ionis and AstraZeneca's eplontersen, an antisense drug (a strand that mops up a gene's messenger RNA), showed essentially no benefit when added on top of the standard stabilizer tafamidis in ATTR cardiomyopathy, a heart disease caused by a misfolded protein. As one panelist put it after checking with the company, "no benefit means no benefit... there's not even a biological effect," which he called "pretty shocking." Alnylam's stock "opened up about 17%" on the read-through that its rival RNA interference silencers would own the market. The takeaway the panel kept circling: for most targets, "sRNA [RNAi] drugs in this space are more potent" than antisense, a live debate as the same silencing tools get pointed at cholesterol, the liver, and beyond. (Biotech Hangout, Jul 10)

Read-throughs & names in play

  • Eli Lilly (LLY). The quiet center of gravity again. It owns the Verve editor behind this week's headline cholesterol data, a dealmaker is reportedly hinting at near-weekly acquisitions funded by weight-loss cash, and its stock made a new high as money rotated into pharma. Bull: an editing platform layered on the biggest cash machine in the industry. Bear: the stock is "extended" after a big run, per the technicians. (Good Medicine Podcast; Stock Market Today With IBD)
  • CRISPR Therapeutics (CRSP) / Intellia (NTLA). The cleanest liquid proxies for the "one-shot editing goes mainstream" narrative, and both named as technical breakouts. Bull: the science headlines and the sector rotation are finally aligned. Bear: already run hard since mid-May and "getting a bit extended." (The KE Report)
  • AbbVie (ABBV). Bought Apogee in one of the month's three mega-deals, cited across multiple podcasts as evidence that immunology (and biotech M&A generally) is red hot. Bull: an active, well-funded acquirer in a hot deal market. Bear: paying up near the top of a euphoric tape. (Investing Experts; Business Of Biotech, Jul 6)
  • Alnylam / Ionis (RNAi vs. antisense). The eplontersen miss removed a competitor and handed Alnylam a one-day 17% pop, but the panel's nuance matters: Alnylam still owes a hefty royalty to Sanofi on its current drug, so its long-term value leans on a next-gen silencer succeeding in an ongoing heart-outcomes trial. Bull: RNAi looks more potent than antisense for these targets. Bear: the trial population is mostly stabilizer-treated, so the read may be murkier than the pop suggests. (Biotech Hangout)
  • Agilent (A), the tools name that actually showed up. On Mendelspod, Agilent's chief medical officer and a Dartmouth genomics director detailed Agilent's partnership with Oxford Nanopore to bring long-read DNA sequencing into the clinic, with Agilent supplying the sample-prep chemistries, DNA quality control, and lab automation. The real-world hook: Dartmouth can now diagnose a leukemia patient, "every single mutation... within 24 hours", versus the two-to-three-week wait patients used to sit through. Bull: a concrete, cost-conscious clinical use case (and a picks-and-shovels role in a growing sequencing market). Bear: still early, and it's one collaboration, not a book-to-bill datapoint. (Mendelspod Podcast, Jul 9)
  • NGS demand, broadly (read-through for sequencing and diagnostics). On Healthcare Unfiltered, oncologist Ezra Cohen of Tempus argued comprehensive tumor testing (a large panel plus whole-transcriptome) turns up an actionable mutation in "15 to 20% of patients... that would not have been picked up on limited testing", yet adoption lags badly, with "only 30%" of early-stage lung-cancer patients getting tested. He's bullish on liquid biopsy and MRD (blood tests that track tiny amounts of tumor DNA). The demand runway for sequencing content is intact even without a specific tools-company readout this week. (Healthcare Unfiltered, Jul 7)
  • China dealmaking (a structural read-through). On Business of Biotech, Sofinnova's Maha Radhakrishnan described a hybrid model taking hold: early trials run in China at "25% or 30%, maybe sometimes even 35% lower" cost, with data quality now approaching "global regulatory quality," then the asset gets re-based in the US or Europe. She flagged pending US legislation (the Biotech Investment National Security Act) that "could possibly dampen some of the activity," and cited Novartis's acquisition of Avidity as proof big pharma is chasing neuromuscular assets. (Business Of Biotech)

On the Alzheimer's front: the tau pivot

No company gave us launch metrics for Leqembi or Kisunla this week, no patient-start numbers, nothing on the under-the-skin injectable version, nothing on brain-swelling monitoring or Medicare coverage. But three independent podcasts converged on the same, more fundamental story, and it's worth capturing because it frames every anti-amyloid stock.

Edinburgh neuroscientist Tara Spires-Jones, on The Naked Scientists, gave the clearest verdict on the current drugs. Both approved amyloid antibodies "did succeed in their primary endpoints of their Phase 3 clinical trials, so they unequivocally work to slow disease progression." The catch: "they're only slowing the disease progression by about 35 or 40%. So you're still getting worse, just more slowly." They can cause "brain bleeding, brain swelling, and rarely even death," and "cost tens of thousands of pounds a year." That cost-benefit math is exactly why, she noted, the UK's regulator has approved them but the NHS "won't pay for them." (The Naked Scientists)

UCSF's Gil Rabinovici, on Brain Talk, added the optimistic counterweight, and the roadmap. He called the antibodies "R-A-Z-T," an analogy to AZT, the first (toxic, so-so) HIV drug that nonetheless "opened the door" to the combinations that made HIV survivable. In his LEADS study of early-onset patients, the 70-plus people on antibody treatment "are progressing more slowly" than matched patients who aren't, "early data to suggest that these drugs are working." He was most excited about diagnosis: a P-tau217 blood test can now determine "with 90% accuracy" whether someone has plaques and tangles, which he called a way to "democratize diagnosis" beyond the few centers with PET scanners. And he pointed straight at the next catalyst: "next month in London, we're going to hear a lot about therapies that are targeting the other bad actor, the tau tangles." (Brain Talk)

That tau focus is where the earliest-stage science is heading. On Science Straight Up, UT Southwestern biochemist Lukasz Joachimiak described designing "artificial chaperones", molecules meant to stop tau from tangling in the first place, using AI-driven molecular design, with the goal of detecting the disease "as early as 20 years of age" and delivering treatment via an AAV gene-therapy injection. He thinks it's "maybe five years" to human trials. He also put a number on the stakes: a USC estimate pegs the societal cost of dementia at "a staggering $818 billion a year." (Science Straight Up, Jul 5)

The investable synthesis: the anti-amyloid launch is a modest, expensive, closely-scrutinized product, and the field itself is telling you the next leg of value creation is tau plus cheap blood-based diagnosis. Watch next month's London conference.

What changed

Last week's issue was about a regulatory thaw, the FDA reversing course on rare-disease gene therapies. This week the story moved from permission to product and money: hard human data that a single infusion can rewrite a cholesterol gene, a technical read that biotech is where capital is rotating, and a running tally of $10B+ takeovers (now Nuvalent, Apogee, and Crinetics) that turns the M&A "race" from anecdote into trend. The China framing also sharpened, less "China is out-innovating everyone" and more "China is the cheap, fast early-trial workshop, with the value re-based to US and European companies," now with a specific US bill (the Biotech Investment National Security Act) hanging over it. (Good Medicine Podcast; Investing Experts; Business Of Biotech)